CuraVac is a clinical-stage biotech developing a new class of Targeted Active Therapies (TAT) for autoimmune diseases. Our first TAT is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' disease, Hashimoto's disease, Type 1 Diabetes, ...
Company Details
- Employees
- 7
- Founded
- 2003
- Address
- Avenue De Villefranche 80, Rixensart,1330,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- curavac.com
- Keywords
- Biotechnology.
- HQ
- Rixensart
Curavac Europe Questions
Curavac Europe's website is curavac.com
Curavac Europe's LinkedIn profile is https://be.linkedin.com/company/curavac
Curavac Europe has
7 employees.
View email and phone details for 7
employees at Curavac Europe.
Curavac Europe's industry is
Biotechnology Research
Curavac Europe's top competitors are
Cognivia,
Syngulon,
Celyad Oncology,
Curevac,
Estetra,
Exo Biologics,
Icosa,
Conveyxo,
Euroscreenfast,
Sagitta Biotech.
Curavac Europe's categories are Biotechnology Research
Curavac Europe's founding year is 2003
